Sanofi ends development of Clostridium difficile vaccine

Sanofi Pasteur, the vaccines business of Sanofi responsible for the program, is informing all investigators, regulatory authorities and trial ethics committees.

Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the phase III Cdiffense clinical trial program concluded that the probability that the study will meet its primary objective is low. Based on this, Sanofi has therefore decided to discontinue clinical development of its experimental Clostridium difficile vaccine, to focus on six key vaccine projects currently in development.

Cdiffense is a trial designed to test the efficacy and safety of a candidate toxoid vaccine in a subpopulation at risk of Clostridium difficile infection.

Sanofi Pasteur, the vaccines business of Sanofi responsible for the program, is informing all investigators, regulatory authorities and trial ethics committees. In addition, investigators are notifying study volunteers of the decision to stop the program. Data from all vaccinated volunteers in this trial will continue to be analyzed for more information and shared with the scientific community.

 
Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Waste management an essential public service in the fight to beat COVID-19
Human chain on International Women's Day by SERAC-Bangladesh
HIV and AIDS: Facts and Forewarning in the context of Bangladesh
Bangladesh will work with UK to fight corona, reiterates PM
Nabila-Manoj in Aryan’s new drama ‘Mon Mondire’
Juventus players agree to take pay reduction in 90-million-euro cost cut

Advertisement

News of the Month

December 2017
S M T W T F S
« Nov   Jan »
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Scroll Up
%d bloggers like this: